Breast Cancer

Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.

Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.

Rachel Layman, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.

Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.

Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.

Sophia R. O'Brien, MD, discusses recent advances in the diagnosis and staging of estrogen receptor–positive metastatic breast cancer.

As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease.

Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.

Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.

Sanjay Goel, MD, MS, expands on the findings from the phase 1b/2 trial, noting the potential benefit this approach may have for patients with cholangiocarcinoma, and detailed next steps for investigating tinengotinib.

Locoregional recurrence rates among patients with favorable-risk, node-positive hormone receptor-positive, HER2-negative breast cancer was not significantly reduced by the addition of regional nodal irradiation to these patient’s treatment regimens.

Two innovative ASCP education initiatives have received accolades from the Alliance for Continuing Education in the Health Professions.

Ian E. Krop, MD, PhD, discusses the use of fam-trastuzumab deruxtecan-nxki across age groups in the DESTINY Breast trials in patients with HER2-positive metastatic breast cancer.

Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

Megan Kruse, MD, offers advice to community oncologists treating HER2+ metastatic breast cancer and discusses unmet needs in the treatment landscape.

Closing out their discussion on fertility preservation in breast cancer, Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, look toward unmet needs and future evolutions in the treatment landscape and offer advice for community physicians.

Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, review fertility preservation strategies in the context of patients with breast cancer undergoing surgery.

The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.

Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.

Sarah Sammons, MD, discusses whether CDK4/6 inhibitors should be considered a standard first line treatment within hormone receptor–positive, HER2-negative advanced breast cancer according to primary results from the phase 3 SONIA trial.